title: Effect of retinoic acid in combination with platelet-derived growth factor-BB or transforming growth factor-beta on tissue inhibitor of metalloproteinases and collagenase secretion from human skin and synovial fibroblasts.
abstract: This report shows for the first time that platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor-beta (TGF-beta) can interact in a synergistic manner with retinoic acid to stimulate the production of tissue inhibitor of metalloproteinases (TIMP) from human skin and synovial fibroblasts. When cells are treated with 1, 10, and 100 ng/ml of either of these growth factors in combination with 10(-5) M retinoic acid, this results in a dose-dependent synergistic induction of TIMP protein secretion which is greater than the additive effect of the agents by up to fourfold. These responses can be inhibited by the presence of specific neutralising antibodies to the growth factors, demonstrating that they are not the result of an experimental artefact such as contamination with bacterial endotoxin. The mechanisms of these synergistic responses may involve the induction of receptors for retinoic acid, PDGF, or TGF-beta or may result from synergistic effects on TIMP gene transcription. We have also found that retinoic acid potently down-regulates PDGF-BB-stimulated collagenase in both types of fibroblast and that the effect of PDGF-BB alone on collagenase secretion from skin fibroblasts is biphasic. Finally, this study reports that retinoic acid and TGF-beta do not act in an additive fashion to inhibit the production of collagenase from skin fibroblasts.
authors.affiliation: Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom.
authors.forename: H F
authors.initials: HF
authors.lastname: Bigg
authors.forename: T E
authors.initials: TE
authors.lastname: Cawston
mesh_terms: D000918:Antibody Specificity; D000077214:Becaplermin; D017364:Collagenases / Q000096:biosynthesis / Q000378:metabolism*; D004357:Drug Synergism; D005347:Fibroblasts / Q000166:cytology / Q000201:enzymology*; D006023:Glycoproteins / Q000096:biosynthesis / Q000378:metabolism*; D006801:Humans; D008297:Male; D009500:Neutralization Tests; D010982:Platelet-Derived Growth Factor / Q000276:immunology / Q000494:pharmacology*; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins / Q000494:pharmacology; D012867:Skin / Q000166:cytology* / Q000201:enzymology; D013583:Synovial Membrane / Q000166:cytology* / Q000201:enzymology; D019714:Tissue Inhibitor of Metalloproteinases; D016212:Transforming Growth Factor beta / Q000276:immunology / Q000494:pharmacology*; D014212:Tretinoin / Q000494:pharmacology*
chemical_list: D006023:Glycoproteins; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D011994:Recombinant Proteins; D019714:Tissue Inhibitor of Metalloproteinases; D016212:Transforming Growth Factor beta; D000077214:Becaplermin; D014212:Tretinoin; D017364:Collagenases